Liver study tests how drug moves in body with scarred livers
NCT ID NCT05045482
First seen Feb 24, 2026 · Last updated Apr 29, 2026 · Updated 8 times
Summary
This study looks at how the drug Saroglitazar is processed in people with mild, moderate, or severe liver scarring (cirrhosis) caused by cholestatic liver disease. About 30 adults will take 1 mg or 2 mg doses daily for 28 days. Researchers will measure drug levels in the blood and check for side effects, comparing results to people with healthy livers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CIRRHOSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Zydus US002
RECRUITINGIndianapolis, Indiana, 46202, United States
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.